The development of imatinib transformed chronic myeloid leukemia (CML) from a disease with a median survival measured in years to one in which most patients achieve normal life expectancy with oral therapy. Understanding how each generation of BCR-ABL (breakpoint cluster region-Abelson) tyrosine kinase inhibitor (TKI) was designed to overcome specific resistance mutations is essential for selecting therapy, managing progression, and anticipating toxicity in clinical practice.
Molecular Target. CML is driven in over 95% of cases by the Philadelphia chromosome, a reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)] that fuses the breakpoint cluster region (BCR) gene to the Abelson (ABL1) tyrosine kinase gene, producing the BCR-ABL1 (breakpoint cluster region-Abelson 1) fusion oncogene.1 The resulting BCR-ABL1 fusion protein is a constitutively active cytoplasmic tyrosine kinase that drives unregulated proliferation, resistance to apoptosis, and genomic instability in hematopoietic stem cells. Unlike normal ABL1, BCR-ABL1 is not subject to autoinhibitory regulation, making it a highly specific pharmacologic target. The same translocation generates the BCR-ABL1 fusion in approximately 25% of adult acute lymphoblastic leukemia (ALL) cases, and TKI-based regimens have substantially improved outcomes in this context as well.
Imatinib: First-Generation BCR-ABL TKI. Imatinib was the first clinically approved TKI and remains a benchmark for targeted cancer therapy. It functions as a competitive inhibitor of the ATP (adenosine triphosphate)-binding site of BCR-ABL1, binding the inactive (DFG-out) conformation of the kinase domain and preventing phosphorylation of downstream substrates.2 Imatinib is also a potent inhibitor of KIT (CD117) and GIST (gastrointestinal stromal tumors; driven by activating KIT or PDGFRA [platelet-derived growth factor receptor alpha] mutations) and in dermatofibrosarcoma protuberans. In CML, response is assessed by three milestones: complete hematologic response (normalization of peripheral blood counts), complete cytogenetic response (CCyR; no Philadelphia-positive metaphases on bone marrow cytogenetics), and MMR (major molecular response; measured as the BCR-ABL1/ABL1 [BCR-ABL1 to total ABL1 transcript] ratio less than 0.1% on the international scale, corresponding to at least a 3-log reduction from standardized baseline).3 Most patients in chronic-phase CML achieve CCyR and MMR on imatinib, but approximately one-third eventually experience resistance or intolerance, necessitating second-generation agents.
Resistance Mechanisms. Resistance to imatinib arises through two broad mechanisms: BCR-ABL1-dependent and BCR-ABL1-independent. BCR-ABL1-dependent resistance most commonly results from point mutations in the kinase domain that destabilize imatinib binding without abolishing kinase activity. Over 100 resistance mutations have been described; the most clinically consequential are those affecting the P-loop (e.g., G250E, Y253H, E255K), the contact residues (e.g., F317L), the activation loop (e.g., H396R), and the gatekeeper residue T315I.4 The T315I (threonine-to-isoleucine substitution at position 315) mutation eliminates a critical hydrogen bond between imatinib and the kinase and also introduces steric hindrance, conferring resistance to all first- and second-generation TKIs. BCR-ABL1-independent resistance mechanisms include gene amplification, clonal evolution with additional chromosomal abnormalities, and activation of alternative signaling pathways such as RAS/MAPK (rat sarcoma virus/mitogen-activated protein kinase) and SRC (proto-oncogene tyrosine-protein kinase Src)-family kinases.
Dasatinib: Second-Generation TKI. Dasatinib is approximately 325-fold more potent than imatinib against BCR-ABL1 and, unlike imatinib, binds both the active and inactive conformations of the kinase, broadening its activity against most imatinib-resistant mutations except T315I.4 It is also a potent SRC-family kinase inhibitor. The most clinically significant adverse effect unique to dasatinib is pleural effusion, occurring in 20-35% of patients on standard dosing, particularly with twice-daily schedules. Once-daily dosing (100 mg/day in chronic-phase CML) substantially reduces pleural effusion risk without compromising efficacy. Pulmonary arterial hypertension (PAH) is a rare but serious complication requiring echocardiographic screening if dyspnea or exercise intolerance develops. Dasatinib also inhibits platelet function through SRC-kinase-dependent mechanisms, increasing bleeding risk independent of thrombocytopenia.
Nilotinib: Second-Generation TKI. Nilotinib is a structurally modified imatinib analog approximately 30-fold more potent than imatinib and active against most imatinib-resistant mutations except T315I and Y253H/E255K (tyrosine-253-histidine and glutamate-255-lysine P-loop) mutations.3 The primary toxicity concerns are cardiovascular: QTc (corrected QT interval) prolongation requiring baseline and periodic electrocardiographic monitoring, peripheral arterial occlusive disease (PAOD), and increased rates of ischemic cardiovascular events. Nilotinib also requires administration on an empty stomach because high-fat meals dramatically increase bioavailability by approximately 80%, raising QTc-related toxicity risk.
Ponatinib: Third-Generation TKI. Ponatinib was rationally designed to accommodate the T315I gatekeeper mutation by introducing a carbon-carbon triple bond (alkyne linker) that bypasses the steric clash created by the isoleucine substitution.5 It is the only approved TKI with consistent activity against T315I BCR-ABL1. However, ponatinib carries a substantial risk of arterial occlusive events that is dose-dependent, occurring in approximately 25-30% of patients over time. The OPTIC (Optimizing Ponatinib Treatment in CML) trial established that starting at 45 mg/day with dose reduction to 15 mg/day upon achieving BCR-ABL1 ratio of 1% or below significantly reduced arterial event rates while maintaining efficacy.
Asciminib: STAMP (Specifically Targeting the ABL Myristoyl Pocket) Inhibitor. Asciminib represents a mechanistically distinct approach, functioning as a STAMP inhibitor rather than an ATP-competitive TKI.6 It binds the myristoyl pocket at the carboxy-terminal lobe of the ABL1 kinase domain, locking the kinase in an inactive conformation through an allosteric mechanism. This means asciminib retains activity against mutations that confer resistance to ATP-competitive TKIs, including T315I at higher doses of 200 mg twice daily. Asciminib was approved based on the Aura3 trial demonstrating superior MMR rates compared to bosutinib in patients who had failed at least two prior TKIs. The primary adverse effects are hypertension, thrombocytopenia, and pancreatic enzyme elevation.
When a patient on imatinib, dasatinib, nilotinib, or bosutinib loses response, BCR-ABL1 kinase domain mutation analysis must be performed before switching therapy. Detection of T315I mandates use of ponatinib or asciminib (200 mg twice daily) — all other approved TKIs are ineffective against T315I. Empiric switching to another second-generation TKI without mutation analysis risks continued treatment failure. Allogeneic stem cell transplantation should be considered concurrently in eligible patients with T315I in accelerated or blast phase.
Treatment-Free Remission. A clinically transformative goal in CML management is treatment-free remission (TFR): discontinuation of TKI therapy in patients who have achieved and sustained DMR (deep molecular response; BCR-ABL1/ABL1 [BCR-ABL1 to total ABL1 transcript] ratio of 0.01% or below, corresponding to MR4 [molecular response 4-log reduction] or deeper) for at least 2-3 years on therapy.3 Approximately 40-60% of patients who meet TFR criteria remain off therapy without molecular relapse at 2 years. Molecular relapse, defined as loss of MMR, typically occurs within the first 6 months after discontinuation and is treated by resuming the prior TKI, with virtually all patients regaining MMR. A withdrawal syndrome of musculoskeletal pain occurs in approximately 30% of patients after TKI discontinuation and is self-limited.
The clinical pharmacology of BCR-ABL (breakpoint cluster region-Abelson) TKIs (tyrosine kinase inhibitors) is dominated by CYP3A4 (cytochrome P450 3A4)-mediated hepatic metabolism and extensive plasma protein binding, creating clinically significant drug-drug interactions that can unpredictably reduce efficacy or amplify toxicity. Understanding these ADME (absorption, distribution, metabolism, excretion) properties is essential for safe prescribing in patients who frequently receive polypharmacy for comorbidities.
Imatinib ADME. Imatinib is well absorbed orally with bioavailability of approximately 98%, largely unaffected by food (though taking with food reduces gastrointestinal irritation). It is highly protein-bound (approximately 95%), primarily to albumin and alpha-1-acid glycoprotein (AAG), and distributes widely into tissues with a volume of distribution of approximately 435 liters.2 Imatinib is metabolized primarily by CYP3A4 to its active N-demethylated metabolite CGP74588 (the primary pharmacologically active metabolite of imatinib), which has comparable potency and contributes meaningfully to overall pharmacologic activity. CYP1A2 (cytochrome P450 1A2), CYP2D6 (cytochrome P450 2D6), and CYP2C9 (cytochrome P450 2C9) play minor roles. Elimination is predominantly fecal (68%) with renal excretion of approximately 13%; the half-life is approximately 18 hours for imatinib and 40 hours for CGP74588, supporting once-daily dosing.
CYP3A4 Interactions with Imatinib. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s wort, dexamethasone at high doses) reduce imatinib plasma concentrations by 60-70%, potentially dropping below the therapeutic threshold required for sustained cytogenetic and molecular response.7 In patients requiring enzyme-inducing anticonvulsants or rifampin for tuberculosis, imatinib doses may need to be increased by approximately 50% and plasma concentration monitoring is advisable. Conversely, strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) increase imatinib exposure by approximately 40%. Imatinib itself is an inhibitor of CYP3A4 (moderate), CYP2D6, and CYP2C9, meaning it can elevate concentrations of co-administered substrates including simvastatin and other statins, warfarin (increased INR risk), and cyclosporine. Patients on warfarin should be switched to low-molecular-weight heparin when feasible, or INR monitoring should be substantially intensified.
Nilotinib ADME and Food-Drug Interaction. Nilotinib has oral bioavailability of approximately 30-40% under fasting conditions; a high-fat meal increases the AUC (area under the concentration-time curve) by 82% and the maximum concentration (Cmax) by 112%.3 This food-drug interaction is pharmacokinetically dangerous because the QTc-prolonging effect of nilotinib is concentration-dependent, and postprandial dosing can push plasma concentrations into ranges that cause clinically significant QTc prolongation. The prescribing requirement is therefore strict fasting: no food for at least 2 hours before and 1 hour after each dose. Nilotinib is metabolized by CYP3A4 and to a lesser extent by CYP2C8 (cytochrome P450 2C8); it is also a substrate and inhibitor of P-glycoprotein (P-gp) and BCRP (breast cancer resistance protein) efflux transporters. Strong CYP3A4 inhibitors are contraindicated. QTc prolonging agents must be used with caution or avoided.
Dasatinib ADME and Interactions. Dasatinib has variable oral bioavailability (14-34%) that is not substantially affected by food under most conditions, though antacid use reduces absorption significantly by raising gastric pH (dasatinib requires an acidic environment for dissolution).4 Proton pump inhibitors (PPIs) reduce dasatinib AUC by approximately 40-50% and should be avoided; H2 (histamine-2)-receptor antagonists (H2RAs; famotidine, ranitidine class) are preferable if acid suppression is necessary, administered at least 2 hours before or after dasatinib. Antacids should be taken at least 2 hours before or 2 hours after dasatinib. Dasatinib is a CYP3A4 substrate; strong inducers reduce exposure substantially and should be avoided. Its volume of distribution is large (approximately 2,505 liters), reflecting extensive tissue penetration including the central nervous system (CNS).
Ponatinib and Asciminib ADME. Ponatinib is orally bioavailable with a half-life of approximately 24 hours, is greater than 99% protein bound, and is metabolized primarily by CYP3A4 with contributions from CYP2C8 and CYP2D6. CYP3A4 inhibitors increase ponatinib exposure and should prompt dose reduction; strong inducers should be avoided. Asciminib is also orally administered with approximately 72% bioavailability under fasting conditions; food increases its AUC by approximately 62%, and it should therefore be taken consistently either with or without food to maintain predictable exposure. Asciminib is a CYP2C9 and CYP3A4 inhibitor, potentially increasing concentrations of warfarin (via CYP2C9) and other CYP3A4 substrates. It is also a P-gp (P-glycoprotein) inhibitor, which may increase exposure of P-gp substrate drugs such as digoxin.6
Rifampin + any BCR-ABL TKI: substantially reduces TKI exposure; avoid or increase imatinib dose with trough monitoring. Nilotinib + strong CYP3A4 inhibitor or QTc-prolonging drug: contraindicated due to concentration-dependent QTc prolongation risk. Dasatinib + proton pump inhibitor: reduces dasatinib AUC by up to 50%; switch to H2RA administered separately. Imatinib + warfarin: inhibits CYP2C9 and CYP3A4 metabolism of warfarin; frequent INR monitoring mandatory or switch to LMWH. Asciminib + warfarin: CYP2C9 inhibition elevates INR; monitor closely.
Cardiac Monitoring Requirements. Each BCR-ABL TKI (tyrosine kinase inhibitor) carries distinct cardiac monitoring obligations driven by its specific toxicity profile. Nilotinib requires a baseline ECG (electrocardiogram) and repeat ECGs approximately 7 days after initiation and after each dose increase, targeting a QTc below 450 ms; the drug should be held for QTc above 480 ms. Dasatinib requires echocardiographic evaluation if dyspnea develops and periodic blood pressure monitoring. Ponatinib mandates a formal cardiovascular risk assessment before initiation, cardiology consultation for patients with prior cardiovascular events, and blood pressure control to target below 140/90 mmHg during therapy. Asciminib requires blood pressure monitoring and lipase monitoring.56
Hepatic and Hematologic Monitoring. All BCR-ABL TKIs can cause hepatotoxicity and myelosuppression to varying degrees. Imatinib causes hepatotoxicity in approximately 5% of patients. Nilotinib causes hyperbilirubinemia (often indirect, reflecting UGT1A1 inhibition) in up to 60% of patients, which is generally benign but must be distinguished from hepatocellular injury (direct bilirubin elevation). Myelosuppression is most pronounced in the first 3 months of therapy; complete blood count (CBC) monitoring every 2 weeks for the first 3 months, then monthly thereafter, is standard for all agents. Growth factor support (filgrastim) may be used for grade 3-4 neutropenia, but TKI (tyrosine kinase inhibitor) dose reduction is preferred for persistent suppression to avoid masking inadequate response or progression.7
Epidermal growth factor receptor (EGFR) mutations define a pharmacogenomically distinct subset of non-small cell lung cancer (NSCLC) in which TKI (tyrosine kinase inhibitor) therapy produces response rates and progression-free survival far superior to platinum-based chemotherapy. Selecting the correct generation of EGFR TKI based on mutation type, resistance mechanism, and CNS (central nervous system) involvement is one of the most clinically consequential decisions in thoracic oncology.
EGFR Biology and Oncogenic Mutations. EGFR (also designated ErbB1 or HER1) is a transmembrane receptor tyrosine kinase of the ErbB family. Ligand binding induces receptor dimerization and autophosphorylation of the intracellular kinase domain, activating downstream RAS/MAPK (rat sarcoma virus/mitogen-activated protein kinase), PI3K/AKT (phosphoinositide 3-kinase/protein kinase B), and STAT (signal transducer and activator of transcription) signaling cascades that drive proliferation and survival.8 In approximately 10-15% of Western NSCLC patients and 40-50% of East Asian patients with adenocarcinoma histology, the EGFR kinase domain carries activating mutations. The two most common sensitizing mutations are exon 19 deletions (del19; approximately 45% of EGFR-mutant NSCLC) and the L858R (leucine-to-arginine substitution at position 858) point mutation in exon 21 (approximately 40%).9 Together, del19 and L858R account for approximately 85% of all EGFR-mutant NSCLC cases. Uncommon mutations (G719X [glycine-719-any amino acid], S768I [serine-768-isoleucine], L861Q [leucine-861-glutamine], and exon 20 insertions) account for the remainder, with exon 20 insertions being largely resistant to standard EGFR TKIs.
First-Generation EGFR TKIs: Gefitinib and Erlotinib. Gefitinib and erlotinib are reversible, ATP (adenosine triphosphate)-competitive inhibitors of the EGFR kinase domain with selectivity for mutant EGFR over wild-type. Both demonstrated superior progression-free survival (PFS) compared to platinum doublet chemotherapy in multiple randomized trials in EGFR-mutant NSCLC: gefitinib (IPASS trial), erlotinib (EURTAC, OPTIMAL trials).9 Median PFS with first-generation TKIs in EGFR-mutant NSCLC is approximately 9-13 months. The exon 19 deletion genotype is associated with better outcomes than L858R with first- and second-generation TKIs, though this difference is attenuated with osimertinib. Both drugs are no longer preferred as first-line therapy given the superior efficacy of osimertinib demonstrated in the FLAURA (First-Line Osimertinib) trial, but they remain relevant in resource-limited settings.
Second-Generation EGFR TKIs: Afatinib and Dacomitinib. Afatinib is an irreversible (covalent) pan-ErbB inhibitor that permanently inactivates EGFR, HER2 (human epidermal growth factor receptor 2), and HER4 (human epidermal growth factor receptor 4) by forming a covalent bond with cysteine 797 in the kinase domain.9 Compared to gefitinib, afatinib demonstrated superior PFS (progression-free survival) in the Lux-Lung 7 trial (a randomized phase IIb study of afatinib vs. gefitinib), with particularly pronounced benefit for exon 19 deletion patients. Afatinib also has activity against certain uncommon EGFR mutations (G719X, L861Q, S768I) for which osimertinib data are more limited. Dacomitinib, another irreversible pan-ErbB TKI, demonstrated superior PFS vs. gefitinib in the Archer 1050 trial (a dacomitinib vs. gefitinib randomized controlled trial) but is rarely used in practice given the osimertinib standard. Neither afatinib nor dacomitinib overcomes the T790M (threonine-to-methionine at position 790) resistance mutation that emerges in approximately 50-60% of patients progressing on first- or second-generation EGFR TKIs.
T790M Resistance and Third-Generation TKIs. The T790M [threonine-to-methionine at position 790] gatekeeper mutation in EGFR, analogous to T315I (threonine-to-isoleucine at position 315) in BCR-ABL1 (breakpoint cluster region-Abelson 1), is the most common acquired resistance mechanism to first- and second-generation EGFR TKIs.9 It restores the affinity of the mutant kinase for ATP and introduces steric hindrance that impairs binding of first-generation agents. T790M is detected in circulating tumor DNA (ctDNA) from plasma or in rebiopsy tumor tissue at progression; plasma ctDNA testing is the preferred first approach. Osimertinib (third-generation, irreversible EGFR TKI) was specifically designed to overcome T790M by selectively targeting both the primary sensitizing mutation and T790M while sparing wild-type EGFR to a greater degree. The Aura3 trial (a randomized trial of osimertinib versus platinum-based doublet chemotherapy) demonstrated superior OS (overall survival; 38.6 vs. 31.8 months median) compared to gefitinib or erlotinib as first-line therapy in EGFR-mutant NSCLC.10
Osimertinib in First-Line Therapy. The FLAURA trial demonstrated that osimertinib produces significantly superior PFS (18.9 vs. 10.2 months) and overall survival compared to gefitinib or erlotinib as first-line therapy in EGFR-mutant NSCLC, establishing it as the first-line standard of care regardless of T790M status at baseline.10 A key driver of osimertinib’s superiority is its exceptional CNS penetration: the drug reaches therapeutic concentrations in cerebrospinal fluid (CSF), producing CNS response rates of approximately 70-80% in patients with brain metastases. The FLAURA2 (FLAURA2 Osimertinib Plus Chemotherapy) trial further demonstrated that the combination of osimertinib with platinum-pemetrexed chemotherapy prolongs PFS compared to osimertinib monotherapy in suitable patients.
Osimertinib achieves CSF-to-plasma concentration ratios of approximately 2-3%, which translates to concentrations substantially above the in vitro IC90 (concentration inhibiting 90% of cells) for EGFR-mutant tumor cells. This CNS penetration allows osimertinib monotherapy to replace whole-brain radiation therapy as initial management for asymptomatic or minimally symptomatic CNS metastases in EGFR-mutant NSCLC, avoiding the neurocognitive sequelae of upfront brain radiation. Stereotactic radiosurgery is reserved for symptomatic lesions or those failing osimertinib. This represents a paradigm shift from the chemotherapy era, when brain metastases in EGFR-mutant NSCLC required separate local modality treatment in virtually all cases.
The toxicity profile of EGFR (epidermal growth factor receptor) TKIs (tyrosine kinase inhibitors) is largely class-driven by on-target inhibition of EGFR in skin, gut, and lung epithelium, but each agent carries agent-specific toxicities that require individualized monitoring. Resistance after osimertinib is mechanistically heterogeneous and defines an area of active investigation where no standard of care is yet established.
Dermatologic Toxicity. Acneiform (papulopustular) rash is the most common class-wide toxicity of EGFR TKIs, occurring in 50-80% of patients and reflecting on-target EGFR inhibition in the basal layer of the epidermis.8 The rash typically appears within the first 2 weeks of therapy, predominantly on the face, scalp, neck, upper chest, and upper back, and has a distinctive follicular distribution. Paradoxically, the severity of acneiform rash is a positive predictive biomarker for tumor response and overall survival. Management follows a graded approach: topical clindamycin or minocycline for grade 1, oral doxycycline or minocycline for grade 2, and TKI (tyrosine kinase inhibitor) dose reduction for grade 3-4 rash. Prophylactic doxycycline (100 mg twice daily for the first 6 weeks of therapy) has been shown in randomized studies to reduce the incidence and severity of grade 2 or higher rash. Afatinib causes the most severe dermatologic toxicity due to irreversible pan-ErbB inhibition.
Gastrointestinal Toxicity. Diarrhea occurs in 20-60% of patients on EGFR TKIs and is particularly prominent with second-generation agents due to HER2 (human epidermal growth factor receptor 2) inhibition in intestinal epithelium, which disrupts chloride secretion regulation. Afatinib causes grade 3 or higher diarrhea in approximately 14% of patients at the 40 mg starting dose. Management includes early initiation of loperamide at the first unformed stool and dose reduction for persistent grade 2 or any grade 3 diarrhea. Hepatotoxicity (transaminase elevation) occurs with all agents and requires monthly monitoring for the first 3 months.
Interstitial Lung Disease. Interstitial lung disease (ILD) or pneumonitis is the most serious class-wide toxicity of EGFR TKIs, occurring in approximately 1-3% of Western patients and 3-4% of Japanese patients (with a higher mortality rate in Japanese patients reported in post-marketing surveillance of gefitinib).8 ILD typically presents within the first 4 weeks to 3 months of therapy with new-onset dyspnea, cough, and low-grade fever; high-resolution CT (computed tomography) reveals bilateral ground-glass opacities or diffuse alveolar damage patterns. Management requires immediate TKI discontinuation, high-dose systemic corticosteroids, and hospitalization for severe cases. EGFR TKI therapy is permanently discontinued after grade 3 or 4 ILD.
Osimertinib-Specific Toxicities. Osimertinib carries additional toxicity risks not shared by first-generation agents. Cardiac toxicity, specifically a reduction in left ventricular ejection fraction (LVEF) by 10 percentage points or more, occurs in approximately 2-4% of patients and is thought to reflect off-target inhibition of ErbB4 in cardiomyocytes.10 Baseline echocardiography is recommended, with repeat assessment for symptoms or signs of cardiac dysfunction. QTc prolongation occurs in approximately 5% of patients. Compared to first-generation TKIs, osimertinib produces less severe dermatologic and gastrointestinal toxicity due to its relative sparing of wild-type EGFR.
EGFR TKI ADME (Absorption, Distribution, Metabolism, Excretion). All approved EGFR TKIs are administered orally. Gefitinib has bioavailability of approximately 60%, undergoes extensive CYP3A4 (cytochrome P450 3A4) metabolism, and has a half-life of approximately 28 hours. Erlotinib bioavailability is approximately 60% under fasted conditions and increases substantially with food; it is also metabolized by CYP3A4 and to a lesser extent CYP1A2 (cytochrome P450 1A2), making it susceptible to induction by smoking. Afatinib has bioavailability of approximately 92% under fasted conditions and undergoes minimal CYP (cytochrome P450 enzyme) metabolism, being eliminated predominantly through fecal excretion of parent drug; it is a P-gp (P-glycoprotein) and BCRP (breast cancer resistance protein) substrate. Osimertinib bioavailability is approximately 70%, metabolized by CYP3A4 to two pharmacologically active metabolites with EGFR inhibitory activity (designated Az5104 and Az7550 in the osimertinib development program), with a long half-life of approximately 48 hours. Strong CYP3A4 inducers (rifampin, carbamazepine) reduce osimertinib AUC (area under the concentration-time curve) by approximately 78% and should be avoided; if unavoidable, increasing the osimertinib dose to 160 mg/day may partially compensate.9
Resistance After Osimertinib. Unlike resistance to first-generation EGFR TKIs (dominated by T790M [threonine-to-methionine at position 790] in approximately 60% of cases), resistance to first-line osimertinib is mechanistically heterogeneous, with no single mechanism predominating. Identified mechanisms include tertiary EGFR mutations (C797S [cysteine-to-serine at position 797], which prevents covalent bond formation by osimertinib), on-pathway bypass mutations (KRAS [Kirsten rat sarcoma viral proto-oncogene] amplification, MET [mesenchymal-epithelial transition factor] amplification, HER2 amplification), histologic transformation (approximately 15% of cases undergo transformation to small cell lung cancer), and emergence of other driver alterations. The C797S mutation in cis with T790M and del19 confers resistance to all approved EGFR TKIs; if C797S occurs in trans with T790M, first-generation TKI plus osimertinib combination can overcome resistance. Liquid biopsy (plasma ctDNA) at progression from osimertinib is the preferred initial resistance analysis, with tissue rebiopsy performed when ctDNA is uninformative or when histologic transformation is clinically suspected.10
Exon 20 insertion mutations (approximately 4% of EGFR-mutant NSCLC) are largely resistant to standard EGFR TKIs including osimertinib at approved doses. They are now recognized as a distinct molecular subtype with dedicated therapies: amivantamab (EGFR-MET bispecific antibody) and mobocertinib (an EGFR TKI designed for exon 20 insertions) are approved in the post-platinum setting. Clinical vignettes presenting an adenocarcinoma with EGFR mutation that fails first-line osimertinib immediately should prompt consideration of whether the EGFR mutation is an exon 20 insertion (requiring reflex genotyping at the outset).
Anaplastic lymphoma kinase (ALK) rearrangements and ROS1 (ROS proto-oncogene 1) fusions define molecularly distinct subsets of NSCLC (non-small cell lung cancer) that are exquisitely sensitive to targeted TKI (tyrosine kinase inhibitor) therapy. The clinical development of ALK inhibitors has closely paralleled the EGFR (epidermal growth factor receptor) paradigm, with successive generations designed to overcome resistance mutations and improve CNS (central nervous system) penetration in a disease where brain metastases are common and life-limiting.
ALK Rearrangements in NSCLC. ALK gene rearrangements, most commonly the EML4 (echinoderm microtubule-associated protein-like 4)-ALK fusion, occur in approximately 3-5% of NSCLC, predominantly in younger patients, never or light smokers, and adenocarcinoma histology.11 The EML4 (echinoderm microtubule-associated protein-like 4)-ALK fusion protein constitutively activates ALK kinase signaling, driving proliferation through RAS/MAPK (rat sarcoma virus/mitogen-activated protein kinase), PI3K/AKT (phosphoinositide 3-kinase/protein kinase B), and JAK/STAT3 (Janus kinase/signal transducer and activator of transcription 3) pathways. Multiple EML4 (echinoderm microtubule-associated protein-like 4)-ALK fusion variants (V1, V2, V3 and others) exist; fusion variant influences resistance mutation patterns and clinical behavior. ALK rearrangement testing is performed by FISH (fluorescence in situ hybridization), IHC (immunohistochemistry), or NGS (next-generation sequencing); comprehensive genomic profiling has become standard at diagnosis. ALK and EGFR mutations are mutually exclusive, as are ALK and RAS (rat sarcoma viral proto-oncogene) mutations.
Crizotinib: First-Generation ALK Inhibitor. Crizotinib was the first approved ALK inhibitor and also inhibits MET (mesenchymal-epithelial transition factor) and ROS1 kinases, giving it activity against three distinct molecular targets.11 In the Profile 1007 and Profile 1014 studies (two pivotal randomized controlled trials of crizotinib vs. chemotherapy), crizotinib demonstrated superior response rates and PFS (progression-free survival) compared to chemotherapy in ALK-positive NSCLC.
However, crizotinib has poor CNS penetration (CSF [cerebrospinal fluid]-to-plasma ratio approximately 0.0026%), and because ALK-positive NSCLC carries a high propensity for brain metastasis, CNS progression while on crizotinib is the dominant mode of therapy failure even in patients with maintained systemic disease control. Resistance mutations in the ALK kinase domain (L1196M [leucine-to-methionine at position 1196] gatekeeper mutation, G1269A, C1156Y, and others) also emerge. Crizotinib is now preferred only in resource-limited settings. Crizotinib ADME (absorption, distribution, metabolism, excretion): oral bioavailability approximately 43%, metabolized by CYP3A4/5 (cytochrome P450 3A4 and 3A5), half-life approximately 42 hours; strong CYP3A4 (cytochrome P450 3A4) inhibitors increase and inducers decrease exposure substantially. Notable toxicities include vision disorders (photopsia, blurred vision occurring in up to 60% of patients), bradycardia, and transaminase elevation.
Alectinib: Second-Generation ALK Inhibitor. Alectinib is a highly selective ALK inhibitor that is substantially more potent than crizotinib, overcomes most crizotinib-resistant ALK mutations, and achieves CSF-to-plasma ratios of approximately 63-94% in animal models, translating to high CNS concentrations in clinical practice.12 The ALEX (Alectinib versus Crizotinib in Untreated ALK-positive Lung Cancer) trial demonstrated that alectinib produced significantly superior PFS (34.8 vs. 10.9 months) and CNS response rates compared to crizotinib as first-line therapy in ALK-positive NSCLC, establishing alectinib as the standard of care. Alectinib is administered at 600 mg twice daily with food (food increases absorption approximately 3-fold, so consistent administration with a meal is mandatory). Tolerability of alectinib is excellent: the most common adverse effects are constipation, peripheral edema, myalgia, photosensitivity reactions, and CPK (creatine phosphokinase) elevation. Unlike crizotinib, alectinib does not cause significant QTc prolongation or vision disorders.
Lorlatinib: Third-Generation ALK Inhibitor. Lorlatinib is the third-generation ALK inhibitor specifically designed to overcome resistance to second-generation ALK TKIs, including the G1202R (glycine-to-arginine at position 1202) solvent-front mutation that confers resistance to alectinib and brigatinib.12 Lorlatinib achieves excellent CNS penetration (CSF-to-plasma ratio approximately 75%). The CROWN (Lorlatinib vs. Crizotinib in Untreated ALK-positive NSCLC) trial demonstrated superior PFS with first-line lorlatinib vs. crizotinib, with CNS intracranial response rates of approximately 82% in patients with CNS metastases. However, lorlatinib causes CNS adverse effects in approximately 20-30% of patients (cognitive effects including memory impairment, mood changes, and psychosis), and hypercholesterolemia occurs in nearly all patients requiring statin therapy in most cases. Lorlatinib is a moderate CYP3A4 inducer, reducing the efficacy of hormonal contraceptives; a non-hormonal method or IUD (intrauterine device) is mandatory during lorlatinib therapy.
Brigatinib and ROS1 Inhibitors. Brigatinib is a second-generation ALK (anaplastic lymphoma kinase)/EGFR (epidermal growth factor receptor) inhibitor with excellent CNS penetration. The ALTA-1L (Brigatinib vs. Crizotinib in ALK-positive NSCLC) trial demonstrated superior PFS vs. crizotinib. A notable early adverse event unique to brigatinib is early-onset pulmonary toxicity (dyspnea, hypoxia) occurring in approximately 3-9% of patients within the first 7 days, requiring early dose interruption. For ROS1 fusions, which occur in approximately 1-2% of NSCLC (most commonly CD74-ROS1), crizotinib has substantial activity (response rate approximately 72%, median PFS approximately 19 months in the expansion cohort of the Profile 1001 study).11 Entrectinib is an ALK/ROS1/TRK (tropomyosin receptor kinase) inhibitor with CNS penetration superior to crizotinib and is now an approved first-line option for ROS1-positive NSCLC. Repotrectinib demonstrates activity against ROS1 G2032R (glycine-to-arginine at position 2032) solvent-front mutation, the dominant resistance mutation after prior ROS1 TKI.
ALK TKI Monitoring and Drug Interactions. All ALK TKIs are CYP3A4 substrates and share the class interaction with CYP3A4 inducers and inhibitors. Alectinib should be taken with food consistently. Lorlatinib is both a CYP3A4 substrate and a moderate CYP3A4 inducer, creating autoinduction and affecting co-administered CYP3A4 substrates including hormonal contraceptives. Crizotinib is both a CYP3A4 substrate and a moderate inhibitor. For lorlatinib, lipid monitoring (fasting lipid panel at baseline and every 3 months) and neuropsychiatric symptom assessment at each visit are components of the monitoring schedule. Bradycardia monitoring is required for crizotinib; ECG (electrocardiogram) monitoring for QTc is appropriate for brigatinib.12
The oncologic practice of molecular testing before initiating systemic therapy has been transformed by the clinical validation of EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), and ROS1 (ROS proto-oncogene 1) as predictive biomarkers. The internist and hospitalist encounter TKI (tyrosine kinase inhibitor)-treated patients across a range of clinical scenarios including toxicity assessment, drug interaction management, and distinguishing disease progression from treatment-related adverse events.
Comprehensive Biomarker Testing at Diagnosis. Current guidelines from ASCO (American Society of Clinical Oncology), NCCN (National Comprehensive Cancer Network), and CAP/IASLC/AMP (College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology) recommend comprehensive molecular profiling by NGS (next-generation sequencing) at the time of initial diagnosis of advanced non-squamous NSCLC (non-small cell lung cancer), with the target panel including at minimum EGFR, ALK, ROS1, BRAF (v-raf murine sarcoma viral oncogene homolog B), MET (mesenchymal-epithelial transition factor), RET (rearranged during transfection proto-oncogene), NTRK (neurotrophic tyrosine receptor kinase), KRAS (Kirsten rat sarcoma viral proto-oncogene), and PD-L1 (programmed death-ligand 1) expression.13 Reflexive simultaneous testing reduces time to appropriate TKI therapy. However, a negative plasma NGS result does not exclude a molecular driver, and tissue-based testing should be performed when plasma is uninformative.
Distinguishing Toxicity from Progression in TKI-Treated Patients. A clinically common and diagnostically challenging scenario is the patient on an EGFR or ALK TKI presenting with new respiratory symptoms. The differential diagnosis must include: (1) disease progression (new or enlarging pulmonary lesions, malignant pleural effusion); (2) drug-induced ILD (interstitial lung disease) or pneumonitis; (3) infection (community-acquired, opportunistic, or atypical); and (4) pulmonary embolism, which occurs at increased rates in patients with thoracic malignancy. CT (computed tomography) of the chest is the initial imaging modality. ILD after EGFR or ALK TKI typically manifests as bilateral, non-segmental ground-glass opacities or consolidation without a new nodular mass consistent with progressive tumor. If ILD is suspected, the TKI must be held immediately while the diagnostic evaluation proceeds; delays in TKI interruption increase the risk of fatal respiratory failure from drug-induced ILD.
Managing TKI Therapy in the Perioperative and Comorbid Setting. Patients on EGFR or ALK TKIs undergoing elective surgery require evaluation of drug interactions with perioperative medications. Key concerns include: QTc monitoring if nilotinib or lorlatinib is continued perioperatively when anesthetics or antiemetics with QTc-prolonging potential are used; CYP3A4 (cytochrome P450 3A4)-based interactions with perioperative antibiotics; and the decision to hold TKI therapy. For most TKIs, a brief perioperative interruption of 3-5 days does not result in disease rebound given the half-lives involved, but the decision should be made in consultation with the treating oncologist. Wound healing concerns, prominent with anti-VEGF agents, are generally not a class concern for TKIs at standard therapeutic doses.
Reproductive Toxicity and Contraception. All BCR-ABL (breakpoint cluster region-Abelson), EGFR (epidermal growth factor receptor), and ALK (anaplastic lymphoma kinase) TKIs are teratogenic and are classified as capable of causing fetal harm if administered during pregnancy. Women of childbearing potential must use highly effective contraception during TKI therapy and for defined periods after completion; the duration depends on the specific TKI’s half-life and metabolite kinetics.9 Lorlatinib is a CYP3A4 inducer that reduces the efficacy of hormonal contraceptives, necessitating use of a non-hormonal method or IUD (intrauterine device) during lorlatinib therapy. Osimertinib should be continued for 6 weeks post-therapy before attempting pregnancy given its long half-life.
Immunization and Infectious Considerations. Patients on BCR-ABL TKIs for CML (chronic myeloid leukemia), and to a lesser degree patients on EGFR or ALK TKIs for NSCLC, have impaired immune surveillance. All patients on long-term TKI therapy should receive annual inactivated influenza vaccination and age-appropriate pneumococcal vaccination. Live attenuated vaccines are contraindicated. HBV (hepatitis B virus) surface antigen and core antibody screening before TKI initiation is recommended, with prophylactic antiviral therapy (entecavir or tenofovir) for patients who are HBsAg-positive, per standard TKI prescribing guidance.13
CML patient losing molecular response on imatinib: order BCR-ABL1 kinase domain mutation analysis before switching; if T315I detected, use ponatinib or asciminib (200 mg twice daily), not second-generation TKIs. EGFR-mutant NSCLC patient on erlotinib progressing after 14 months: test plasma ctDNA for T790M; if positive, switch to osimertinib; if negative, tissue rebiopsy and rule out SCLC transformation. Patient on nilotinib presenting with new chest pain and ST changes: evaluate for myocardial infarction (nilotinib cardiovascular risk) and check ECG for QTc prolongation; review concomitant medications for CYP3A4 inhibitors. ALK-positive NSCLC patient on alectinib presenting with bilateral ground-glass opacities on CT: hold alectinib immediately, evaluate for ILD vs. infection vs. progression; bilateral GGOs favor ILD. Patient on rifampin for latent tuberculosis needing imatinib: expect 60-70% reduction in imatinib exposure; increase imatinib dose to 600-800 mg/day with trough level monitoring.
Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290-293.
doi:10.1038/243290a0Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
doi:10.1056/NEJM200104053441401Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917-927.
doi:10.1056/NEJMoa1609324Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401.
doi:10.1126/science.1099480Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-1796.
doi:10.1056/NEJMoa1306494Rea D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031-2041.
doi:10.1182/blood.2020009984Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-894.
doi:10.2165/00003088-200544090-00001Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21(20):3798-3807.
doi:10.1200/JCO.2003.11.069Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125.
doi:10.1056/NEJMoa1713137Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41-50.
doi:10.1056/NEJMoa1913662Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-2394.
doi:10.1056/NEJMoa1214886Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829-838.
doi:10.1056/NEJMoa1704795Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors. J Clin Oncol. 2018;36(9):911-919.
doi:10.1200/JCO.2017.76.7293